Table 1.
Characteristics of patients enrolled in the programme before delivery.
| N (%) | |
|---|---|
| Age | 23.5 (21–25.2)∗ |
| Height | 152 (148–160)* |
| Underweight (BMI < 18.5) | 122 (39) |
| First pregnancy | 173 (51.49) |
| Education | |
| Higher | 13 (3.88) |
| Secondary | 128 (38.21) |
| Primary | 48 (14.33) |
| No education | 146 (43.58) |
| Smoker | 1 (0.003) |
| CD4 lymphocyte count (cells/μL) | |
| <200 | 29 (8.76) |
| 200–350 | 96 (29) |
| 350–500 | 102 (30.82) |
| >500 | 104 (31.42) |
| Time on ART before delivery | |
| <1 day | 23 (6.91) |
| 1–30 days | 53 (15.92) |
| 31–60 days | 48 (14.41) |
| 61–90 days | 54 (16.22) |
| 91–120 days | 40 (12.01) |
| >120 days | 115 (34.53) |
| ART regimen | |
| AZT + 3TC + NVP | 148 (44.05) |
| AZT + 3TC + EFV | 68 (20.24) |
| AZT + 3TC + NFV | 35 (10.42) |
| D4T + 3TC + NVP | 39 (11.61) |
| D4T + 3TC + EFV | 19 (5.65) |
| D4T + 3TC + NFV | 16 (4.76) |
| TDF + 3TC/FTC + LPVr | 5 (1.49) |
| AZT + 3TC + LPVr | 4 (1.19) |
| d4T + 3TC + LPVr | 1 (0.3) |
| TDF+3TC+AZT | 1 (0.3) |
| Home delivery | 24 (7.38) |
| Caesarean section | 125 (39.18) |
| Newborn prophylaxis | |
| AZT | 229 (73.63) |
| AZT + 3TC + NVP | 59 (18.97) |
| NVP | 15 (4.82) |
| None | 8 (2.57) |
| Type of feeding | |
| Formula | 159 (51.29) |
| Breast | 148 (47.74) |
| Mixed | 3 (0.97) |
*Median (interquartile range). BMI: body mass index; ART: antiretroviral treatment; AZT: zidovudine; 3TC: lamivudine; NVP, and nevirapine; EFV, efavirenz; d4T: stavudine; NFV: nelfinavir; TDF: tenofovir; FTC: emtricitabine; LPVr: lopinavir-ritonavir. Missing values for each variable were not included.